drugset
drugset / Trial / NCT03269045

Study of ORL-1B in Patients With Biotinidase Deficiency

NCT03269045 ↗

Phase 1/2 Completed 20 enrolled Orpha Labs
NaSingle-groupOpen-labelTreatment

Summary

An Open-label, Single-arm, Phase 2 Study of Biotin in Patients With Biotinidase Deficiency.

Timeline

Start
2013-08-31
Primary completion
2018-01-01
Completion
2018-01-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Biotin Small molecule — Oral

Indications

biotinidase deficiency